Axorus

Axorus operates at the intersection of ophthalmic medical devices, neurotechnology, nanotechnology, and wearable hardware. Its proposed product addresses retinal blindness through a non-invasive system rather than an implanted retinal prosthesis, gene therapy, or injectable treatment. The approach combines a pigmented contact lens with smart glasses containing a near-infrared laser emitter; the lens is intended to convert projected light into localized ultrasound through patented photoacoustic effects, stimulating surviving retinal neurons. This gives Axorus a distinct technical thesis within vision restoration, but also places it in a clinically demanding category where safety, signal quality, durability, usability, and regulatory validation are decisive. Relative to conventional surgical retinal implants, Axorus emphasizes reversibility and daily wear. Relative to pharmaceutical or genetic approaches, it is device-led and intended to work without modifying biology. Boston University and the Institut de la Vision add research credibility, while the company’s small employee band and seed-stage funding indicate that its competitive position remains technology- and validation-dependent rather than commercial.

Axorus shows an early-stage, research-led trajectory rather than a scaled commercial growth pattern. Founded in 2019, it recorded non-equity assistance on Feb 8, 2019 and raised two seed rounds later that year and in 2020. The Sep 27, 2019 round contributed $905,953, while the Jul 17, 2020 round added $420,548; together, the financings total $1,326,501. Finovam Gestion led both rounds, alongside Nord France Amorcage, Happy Capital, and Eurasante’s participation in the earlier assistance activity. The main product milestone is the articulation of a complete artificial-retina system: a photoacoustic contact lens paired with laser-emitting glasses, rather than a standalone lens or implant. The recorded team remains small, with an employee range of one to ten and two current leadership positions. No hiring acceleration, layoffs, later funding, or product commercialization data is documented through Oct 1, 2026.